Qianjiang Yongan Pharmaceutical Co Ltd (002365) - Total Assets
Based on the latest financial reports, Qianjiang Yongan Pharmaceutical Co Ltd (002365) holds total assets worth CN¥2.26 Billion CNY (≈ $331.06 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Qianjiang Yongan Pharmaceutical Co Ltd (002365) net assets for net asset value and shareholders' equity analysis.
Qianjiang Yongan Pharmaceutical Co Ltd - Total Assets Trend (2006–2024)
This chart illustrates how Qianjiang Yongan Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Qianjiang Yongan Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Qianjiang Yongan Pharmaceutical Co Ltd's total assets of CN¥2.26 Billion consist of 51.9% current assets and 48.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.9% |
| Accounts Receivable | CN¥167.93 Million | 7.3% |
| Inventory | CN¥93.50 Million | 4.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥79.56 Million | 3.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Qianjiang Yongan Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Qianjiang Yongan Pharmaceutical Co Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Qianjiang Yongan Pharmaceutical Co Ltd's current assets represent 51.9% of total assets in 2024, an increase from 42.2% in 2006.
- Cash Position: Cash and equivalents constituted 13.9% of total assets in 2024, up from 11.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 11.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 7.3% of total assets.
Qianjiang Yongan Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Qianjiang Yongan Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Qianjiang Yongan Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.02 | 5.47 | 3.31 |
| Quick Ratio | 4.69 | 5.03 | 3.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥935.22 Million | CN¥931.66 Million | CN¥717.31 Million |
Qianjiang Yongan Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Qianjiang Yongan Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.15 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -1.6% |
| Total Assets | CN¥2.31 Billion |
| Market Capitalization | $590.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Qianjiang Yongan Pharmaceutical Co Ltd's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Qianjiang Yongan Pharmaceutical Co Ltd's assets decreased by 1.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Qianjiang Yongan Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual total assets of Qianjiang Yongan Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.31 Billion ≈ $337.82 Million |
-1.64% |
| 2023-12-31 | CN¥2.35 Billion ≈ $343.46 Million |
-3.18% |
| 2022-12-31 | CN¥2.42 Billion ≈ $354.73 Million |
+6.05% |
| 2021-12-31 | CN¥2.29 Billion ≈ $334.50 Million |
+5.65% |
| 2020-12-31 | CN¥2.16 Billion ≈ $316.62 Million |
+13.41% |
| 2019-12-31 | CN¥1.91 Billion ≈ $279.18 Million |
-1.10% |
| 2018-12-31 | CN¥1.93 Billion ≈ $282.28 Million |
+22.10% |
| 2017-12-31 | CN¥1.58 Billion ≈ $231.19 Million |
+24.08% |
| 2016-12-31 | CN¥1.27 Billion ≈ $186.33 Million |
+5.85% |
| 2015-12-31 | CN¥1.20 Billion ≈ $176.04 Million |
+1.34% |
| 2014-12-31 | CN¥1.19 Billion ≈ $173.70 Million |
-1.27% |
| 2013-12-31 | CN¥1.20 Billion ≈ $175.94 Million |
-0.70% |
| 2012-12-31 | CN¥1.21 Billion ≈ $177.18 Million |
+4.34% |
| 2011-12-31 | CN¥1.16 Billion ≈ $169.81 Million |
+6.39% |
| 2010-12-31 | CN¥1.09 Billion ≈ $159.61 Million |
+176.83% |
| 2009-12-31 | CN¥394.00 Million ≈ $57.65 Million |
+3.91% |
| 2008-12-31 | CN¥379.16 Million ≈ $55.48 Million |
+49.03% |
| 2007-12-31 | CN¥254.42 Million ≈ $37.23 Million |
+68.24% |
| 2006-12-31 | CN¥151.23 Million ≈ $22.13 Million |
-- |
About Qianjiang Yongan Pharmaceutical Co Ltd
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmace… Read more